CKD 942
Alternative Names: CKD942Latest Information Update: 17 Jan 2018
At a glance
- Originator Chong Kun Dang
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Idiopathic pulmonary fibrosis
Most Recent Events
- 17 Jan 2018 Discontinued - Phase-II for Idiopathic pulmonary fibrosis in South Korea (unspecified route) (Chong Kun Dang Pharmaceutical pipeline, January 2018)
- 15 Dec 2015 Phase-II clinical trials in Idiopathic pulmonary fibrosis in South Korea (unspecified route)